ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2189

Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study

Salvatore De Vita1, Raphaèle Seror2, Luca Quartuccio3, Frederic Desmoulins4, Sara Salvin5, Gabriel Baron6, Martina Fabris7, Philippe Ravaud8, Miriam Isola9 and Xavier Mariette10, 1Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 2Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, 3Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 4Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, 5Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, 6Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, 7Institute of Clinical Pathology, Udine, Italy, 8Epidemiology, Université Paris-Descartes, Paris, Paris, France, 9Institute of Statistics, DSMB, University of Udine, Udine, Italy, 10Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: belimumab and clinical trials, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Session Title: Sjögren's Syndrome - Clinical

Session Type: Abstract Submissions (ACR)

Background/Purpose:

to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score and the single ESSDAI domains.

Methods:

Thirty patients (15+15) with pSS (positive classification criteria and positive anti-SSA/SSB antibodies) were investigated in two European Centres to assess the efficacy and safety of BEL in pSS. They were all females (49.5±16.5 years). At least one of the following items was needed for enrolment: a) parotid swelling and/or systemic involvement; b) objective sicca with at least one laboratory sign of B-cell hyperactivation in serum (increased IgG, increased free Ig light chains, increased beta2-microglobulin, decreased C4, monoclonal gammopathy or cryoglobulinemia); c) recent onset of sicca symptoms (<5 years). Belimumab 10 mg/kg was administered intravenously on days 0, 14, 28 and then every 28 days through 48 wks, with a final evaluation at wk52, and after drug suspension. Concomitant therapies were left unchanged.

Results:

29/30 patients completed the 28 wk infusions, and 1 case with lymphoma and cryoglobulinemic vasculitis was withdrawn at w12 for worsening. Wk52 data are available in one Centre.

At wk 28, the ESSDAI score decreased from a median of 7 (1-33) to 4 (0-23) (p= 0.0001, Wilcoxon) with a decrease of ≥ 3 points in 14/29 (48.3%) and of ≥ 2 points in 18/29 (62.1%). The following domains mainly contributed to the ESSDAI score at baseline: glandular, biological, lymphadenopathy, articular, haematological and pulmonary.  Activity (low-moderate-high) was present (baseline vs. wk28) in these domains as follows: glandular 15/30 vs. 7/29; biologic 27/30 vs. 20/29; lymphadenopathy 9/30 vs. 3/29; articular 9/30 vs. 3/29; haematological 5/30 vs. 3/29; pulmonary 4/30 vs. 5/29.

At wk 28 the glandular domain improved in 10/13 (76.9%) patients with non-malignant parotid swelling (confirmed by biopsy, whenever possible), while no improvement occurred in 2/2 patients with parotid low-grade lymphoma (stage IE). Data available at wk52 showed persistent disappearance of swelling in 4/5 patients and further amelioration in 1/5. After BEL suspension parotid swelling relapsed in 2/5 of these responders (4 and 14 months later).

Overall, 13/15 patients completed the trial at w52 in one Centre. The median ESSDAI at wk52 was 2 (0-12) [vs. 3 (1-16) at w28 vs. 8 (2-33) at baseline; p=0.003, wk52 vs. baseline, Wilcoxon)], with activity in the ESSDAI domains (baseline vs. wk28 vs. wk52) as follows: glandular 7/15 vs. 2/14 vs. 2/13; biologic 13/15 vs. 11/14 vs. 10/13; lymphadenopathy 8/15 vs. 3/14 vs. 0/13; articular 4/15 vs. 0/14 vs. 0/13; 1/15 vs. 1/14 vs. 0/13; pulmonary 2/15 vs. 2/14 vs. 2/13.

At wk52 we no additional side effects, if compared to wk28, were observed in the available cases.

Conclusion:

Belimumab proved to be beneficial for non malignant glandular swelling in pSS. Recently, BAFF serum level were significantly increased in this subset of patients (Quartuccio L. et al., Rheumatology 2012, in press), supporting the rationale and the results observed. Other systemic features of pSS might also improve with BEL therapy. A controlled randomized trial is advisable.


Disclosure:

S. De Vita,

Human Genome Sciences, Inc.,

2;

R. Seror,

Human Genome Sciences, Inc.,

2,

GlaxoSmithKline,

5;

L. Quartuccio,
None;

F. Desmoulins,
None;

S. Salvin,
None;

G. Baron,
None;

M. Fabris,
None;

P. Ravaud,
None;

M. Isola,
None;

X. Mariette,

Human Genome Sciences, Inc.,

2,

GlaxoSmithKline,

5.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-belimumab-on-non-malignant-parotid-swelling-and-systemic-manifestations-of-sjogrens-syndrome-results-of-the-beliss-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies